Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opp...
NexGel, Inc (NXGL)
Company Research
Source: Yahoo! Finance
Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors. Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a
Show less
Read more
Impact Snapshot
Event Time:
NXGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NXGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NXGL alerts
High impacting NexGel, Inc news events
Weekly update
A roundup of the hottest topics
NXGL
News
- NexGel (NXGL) had its price target lowered by Maxim Group from $6.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]Yahoo! Finance
- NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial ProductsGlobeNewswire
- NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]Yahoo! Finance
- NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial ProductsGlobeNewswire
NXGL
Analyst Actions
- 3/12/26 - Maxim Group
NXGL
Sec Filings
- 3/12/26 - Form SCHEDULE
- 3/10/26 - Form 8-K
- 2/11/26 - Form 8-K
- NXGL's page on the SEC website